Know Cancer

or
forgot password

Social Anxiety and Avoidance in Head and Neck Cancer Patients


N/A
21 Years
70 Years
Not Enrolling
Both
Anxiety Disorder, Head and Neck Cancer, Lung Cancer

Thank you

Trial Information

Social Anxiety and Avoidance in Head and Neck Cancer Patients


OBJECTIVES:

- Determine the relationship between treatment-provoked social anxiety and avoidance in
patients previously treated for head and neck cancer.

- Determine the relationship between pre-cancer psychiatric diagnosis and post-treatment
social anxiety and avoidance in these patients.

- Determine the effect of social anxiety and/or avoidance on the quality of life of these
patients.

- Investigate the specificity of these relationships in patients with head and neck
cancer by comparing patients with head and neck cancer to patients with lung cancer.

OUTLINE: This is a cross-sectional study. Patients are stratified according to prior
treatment type (significantly impairing [surgery] vs less impairing
[chemotherapy/radiotherapy]).

Patients undergo a face-to-face interview with a mental health clinician over 2 hours.
Patients complete multiple psychiatric/psychological assessments during the interview,
including the Structured Clinical Interview for DSM-IV (SCID); the Liebowitz Social Anxiety
Scale (SAS); the Performance Status Scale for Head and Neck Cancer Patients (PSS-HN); the
Social Phobia and Anxiety Inventory (SPAI); the State-Trait Anxiety Inventory (STAI);
Response to Stress Questionnaire, Cancer Version (RSQ-CV); the Functional Assessment of
Cancer Therapy (FACT-HNC (head neck cancer) or LC); the Voice Handicap Index (VHI); and the
Body Image Scale (BIS).

Cancer treatment and medical history information are gathered from patients' medical
records.

Inclusion Criteria


PATIENT CHARACTERISTICS:

- Diagnosis of 1 of the following:

- Head and neck cancer

- Lung cancer (control group)

- Must have received treatment for head and neck cancer or lung cancer within the past
5 years

PATIENT CHARACTERISTICS:

- Able to speak and read English to answer surveys, interviews, and questionnaires

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Level of social anxiety and avoidance in HNC patients post-treatment

Outcome Description:

Measured by the Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory, containing 24 items with each item separately rated for fear as 0 (none), 1 (mild), 2 (moderate) to 3 (severe)and for avoidance behavior as 0 (never), 1 (occasionally), 2 (often), to 3 (usually). Scores are summed with lower values indicating lower levels of social anxiety and avoidance.

Outcome Time Frame:

at study entry, day 1

Safety Issue:

No

Principal Investigator

Kirsten Haman, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Vanderbilt-Ingram Cancer Center

Authority:

United States: Federal Government

Study ID:

VICC HN 0397

NCT ID:

NCT00483639

Start Date:

November 2003

Completion Date:

January 2008

Related Keywords:

  • Anxiety Disorder
  • Head and Neck Cancer
  • Lung Cancer
  • anxiety disorder
  • long-term effects secondary to cancer therapy in adults
  • head and neck cancer
  • non-small cell lung cancer
  • small cell lung cancer
  • Anxiety Disorders
  • Head and Neck Neoplasms
  • Lung Neoplasms

Name

Location

Vanderbilt-Ingram Cancer CenterNashville, Tennessee  37232-6838
MBCCOP - Meharry Medical College - NashvilleNashville, Tennessee  37208-3599